Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis

• Published in: Thyroid (New York, N.Y.) Vol. 32; no. 6; p. 725
• Main Authors: Zhou, Jin, Tripathi, Madhulika, Ho, Jia Pei, Widjaja, Anissa Anindya, Shekeran, Shamini Guna, Camat, Macalinao Dominique, James, Anne, Wu, Yajun, Ching, Jianhong, Kovalik, Jean-Paul, Lim, Kiat-Hon, Cook, Stuart Alexander, Bay, Boon-Huat, Singh, Brijesh Kumar, Yen, Paul Michael
• Format: Journal Article
• Language: English
• Published: United States 01.06.2022
• Subjects: Animals; Disease Models, Animal; Drinking Water - metabolism; Fatty Acids - metabolism; Fibrosis; Humans; Inflammation - metabolism; Liver - metabolism; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - metabolism; Thyroid Hormones - metabolism; Triglycerides - metabolism; lipid oxidation; autophagy; mitochondrial biogenesis; lipotoxicity

Nonalcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, lobular inflammation, and fibrosis. Thyroid hormone (TH) reduces steatosis; however, the therapeutic effect of TH on NASH-associated inflammation and fibrosis is not known. This study examined the therapeutic effect of TH on...